TehTarik的个人主页 - 老虎社区

TehTarik

暂无个人介绍

IP属地：未知

3关注

1粉丝

0主题

0勋章

2022-01-01

nice

抱歉，原内容已删除

2022-01-01

wow

抱歉，原内容已删除

2022-01-01

great!

抱歉，原内容已删除

2021-06-25

like

抱歉，原内容已删除

2021-06-25

wah

抱歉，原内容已删除

2021-06-24

like

抱歉，原内容已删除

2021-06-24

Nioo

抱歉，原内容已删除

2021-06-24

like

抱歉，原内容已删除

2021-06-22

wow

If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>

2021-06-22

nice

抱歉，原内容已删除

2021-06-22

man

抱歉，原内容已删除

2021-06-22

wow

抱歉，原内容已删除

2021-06-22

like!

"This Is Not A Temporary Situation": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote>

2021-06-21

like

抱歉，原内容已删除

2021-06-21

like

抱歉，原内容已删除

2021-06-20

like!

抱歉，原内容已删除

2021-06-20

:0

抱歉，原内容已删除

2021-06-18

good!!

抱歉，原内容已删除

2021-06-18

:00

Orphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote>

2021-06-18

like n comment!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573902637171983","uuid":"3573902637171983","gmtCreate":1611756144058,"gmtModify":1611756144058,"name":"TehTarik","pinyin":"tehtarik","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692251955,"gmtCreate":1641003795174,"gmtModify":1641003795174,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692251955","repostId":"2195448557","repostType":4,"isVote":1,"tweetType":1,"viewCount":2813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253758,"gmtCreate":1641003778376,"gmtModify":1641003778376,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253758","repostId":"1114332157","repostType":4,"isVote":1,"tweetType":1,"viewCount":2153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253123,"gmtCreate":1641003752634,"gmtModify":1641003752726,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253123","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122154699,"gmtCreate":1624606940611,"gmtModify":1631890740816,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122154699","repostId":"2146027771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154864,"gmtCreate":1624606929858,"gmtModify":1631890740830,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/122154864","repostId":"1169758731","repostType":4,"isVote":1,"tweetType":1,"viewCount":1382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121269818,"gmtCreate":1624465750834,"gmtModify":1631890740844,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121269818","repostId":"1127255730","repostType":4,"isVote":1,"tweetType":1,"viewCount":3106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285710,"gmtCreate":1624465639130,"gmtModify":1631890740866,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"Nioo","listText":"Nioo","text":"Nioo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121285710","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":2707,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285619,"gmtCreate":1624465614931,"gmtModify":1631890740868,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121285619","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027708,"gmtCreate":1624346334604,"gmtModify":1631890740882,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027708","repostId":"1186855284","repostType":4,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=zh_CN&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<p>  On a strong day for the Nasdaq, two highfliers stood out.  Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-22 14:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  On a strong day for the Nasdaq, two highfliers stood out.  Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq  was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027304,"gmtCreate":1624346321408,"gmtModify":1631890740897,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129027304","repostId":"2145033651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027014,"gmtCreate":1624346306138,"gmtModify":1631890740911,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"man","listText":"man","text":"man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027014","repostId":"1161295709","repostType":4,"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024568,"gmtCreate":1624346293054,"gmtModify":1631890740926,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129024568","repostId":"1139414035","repostType":4,"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024813,"gmtCreate":1624346278732,"gmtModify":1631890740940,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129024813","repostId":"1136223229","repostType":4,"repost":{"id":"1136223229","kind":"news","pubTimestamp":1624345984,"share":"https://www.laohu8.com/m/news/1136223229?lang=zh_CN&edition=full","pubTime":"2021-06-22 15:13","market":"us","language":"en","title":"\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136223229","media":"zerohedge","summary":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same","content":"<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p><p><blockquote>持续的全球半导体短缺导致电子产品价格上涨，同时迫使供应商和材料提供商继续提高价格。在短缺的情况下，对消费电子产品的需求持续飙升。</blockquote></p><p> Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p><p><blockquote>因此，据《新华尔街日报》报道，行业官员认为价格上涨可能会继续。这种影响在消费电子产品中很容易看到。</blockquote></p><p> The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p><p><blockquote>该报告指出，像一台华硕笔记本电脑以前售价900美元，现在售价950美元。一台惠普Chromebook笔记本电脑过去售价220美元，现在价格涨到了250美元。事实上，惠普在短短一年内就将消费PC价格提高了8%，将打印机价格提高了20%以上。该公司首席执行官将价格上涨归咎于“零部件短缺”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p><p><blockquote>戴尔科技公司首席财务官Thomas Sweet最近表示：<b>“当我们考虑零部件成本上涨时，我们将酌情调整定价。”</b></blockquote></p><p> Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p><p><blockquote>伯恩斯坦分析师托尼·萨科纳吉<s>为惠普找借口</s>对价格上涨的解释是，它们反映了缺乏通常的折扣，而不是全面的价格上涨。</blockquote></p><p> Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p><p><blockquote>芯片制造商Analog Devices Inc.的首席执行官Vincent Roche评论道：“我们没有利用这个周期在定价方面做任何事情，除了为我们必须获得的额外供应支付更多费用。我们正在传递这一点。”</blockquote></p><p> Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p><p><blockquote>博通公司首席执行官Hock Tan简单地指出：“我们看到了成本通胀。”</blockquote></p><p> Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p><p><blockquote>Digi-Key Electronics今年还将半导体相关组件的价格提高了约15%。他们将此归咎于“供应紧缩的压力”。<b>该公司全球供应商管理副总裁David Stein表示，某些零部件现在的成本比以前高出40%。</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p><p><blockquote>“自去年年初以来，计算机内存的合同价格上涨了约34%。”<i>杂志</i>指出，物价上涨是“美国经济通胀更广泛上升的一部分”。</blockquote></p><p> The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p><p><blockquote>根据Supplyframe Inc.的数据，自去年年中以来，最畅销的20款微控制器的中值价格上涨了12%以上。</blockquote></p><p> Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p><p><blockquote>电子元器件行业协会首席分析师戴尔·福特总结道：<b>“原材料成本最近上涨更多，我认为人们现在说这不是暂时的情况。价格上涨将是持久的。”</b></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-06-22 15:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p><p><blockquote>持续的全球半导体短缺导致电子产品价格上涨，同时迫使供应商和材料提供商继续提高价格。在短缺的情况下，对消费电子产品的需求持续飙升。</blockquote></p><p> Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p><p><blockquote>因此，据《新华尔街日报》报道，行业官员认为价格上涨可能会继续。这种影响在消费电子产品中很容易看到。</blockquote></p><p> The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p><p><blockquote>该报告指出，像一台华硕笔记本电脑以前售价900美元，现在售价950美元。一台惠普Chromebook笔记本电脑过去售价220美元，现在价格涨到了250美元。事实上，惠普在短短一年内就将消费PC价格提高了8%，将打印机价格提高了20%以上。该公司首席执行官将价格上涨归咎于“零部件短缺”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p><p><blockquote>戴尔科技公司首席财务官Thomas Sweet最近表示：<b>“当我们考虑零部件成本上涨时，我们将酌情调整定价。”</b></blockquote></p><p> Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p><p><blockquote>伯恩斯坦分析师托尼·萨科纳吉<s>为惠普找借口</s>对价格上涨的解释是，它们反映了缺乏通常的折扣，而不是全面的价格上涨。</blockquote></p><p> Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p><p><blockquote>芯片制造商Analog Devices Inc.的首席执行官Vincent Roche评论道：“我们没有利用这个周期在定价方面做任何事情，除了为我们必须获得的额外供应支付更多费用。我们正在传递这一点。”</blockquote></p><p> Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p><p><blockquote>博通公司首席执行官Hock Tan简单地指出：“我们看到了成本通胀。”</blockquote></p><p> Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p><p><blockquote>Digi-Key Electronics今年还将半导体相关组件的价格提高了约15%。他们将此归咎于“供应紧缩的压力”。<b>该公司全球供应商管理副总裁David Stein表示，某些零部件现在的成本比以前高出40%。</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p><p><blockquote>“自去年年初以来，计算机内存的合同价格上涨了约34%。”<i>杂志</i>指出，物价上涨是“美国经济通胀更广泛上升的一部分”。</blockquote></p><p> The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p><p><blockquote>根据Supplyframe Inc.的数据，自去年年中以来，最畅销的20款微控制器的中值价格上涨了12%以上。</blockquote></p><p> Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p><p><blockquote>电子元器件行业协会首席分析师戴尔·福特总结道：<b>“原材料成本最近上涨更多，我认为人们现在说这不是暂时的情况。价格上涨将是持久的。”</b></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136223229","content_text":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.\nErgo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.\nThe report notes that items like one ASUS laptop that formerly cost $900 now costs $950. An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".\nDell Technologies Inc. Chief Financial Officer Thomas Sweet recently said: “As we think about component cost increases, we’ll adjust our pricing as appropriate.”\nBernstein analyst Toni Sacconaghimade excuses for HPexplained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.\nVincent Roche, the CEO of chip maker Analog Devices Inc., commented: “We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”\nHock Tan, CEO of Broadcom Inc., simply noted: “We see cost inflation.”\nDigi-Key Electronics has also raised prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".Certain components now cost 40% more than they used to, according to David Stein, the company’s vice president of global supplier management.\n\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the Journalnotes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".\nThe median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to Supplyframe Inc.\nDale Ford, the chief analyst at the Electronic Components Industry Association, concluded: “Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,"SPY":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167303200,"gmtCreate":1624245214400,"gmtModify":1631892937410,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167303200","repostId":"2145707918","repostType":4,"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167309877,"gmtCreate":1624245184099,"gmtModify":1631892937423,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167309877","repostId":"2145700634","repostType":4,"isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164045216,"gmtCreate":1624162915335,"gmtModify":1631892937432,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164045216","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164042708,"gmtCreate":1624162897804,"gmtModify":1631892937445,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":0","listText":":0","text":":0","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164042708","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166652695,"gmtCreate":1624007827517,"gmtModify":1631892937456,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"good!!","listText":"good!!","text":"good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166652695","repostId":"1164089282","repostType":4,"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664750,"gmtCreate":1624006893770,"gmtModify":1631892937476,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":00","listText":":00","text":":00","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664750","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://www.laohu8.com/m/news/1142916683?lang=zh_CN&edition=full","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p><p><blockquote>Orphazyme股价在盘前交易中暴跌超过60%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p><p><blockquote>在美国卫生监管机构拒绝其关键候选药物后，Orphazyme周五大幅下调了财务预测。</blockquote></p><p> Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p><p><blockquote>Orphazyme表示，其申请FDA批准arimoclomol（一种治疗遗传性疾病尼曼-皮克病C型的药物）的申请尚未成功。</blockquote></p><p> As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p><p><blockquote>因此，该公司预计今年的收入将低于此前预期，运营亏损将大幅扩大，迫使该公司削减成本。</blockquote></p><p> \"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p><p><blockquote>经纪商Nordnet在给客户的一份报告中写道：“Orphazyme没有钱，也没有实质性的项目……投资者将资金投入到‘模因倾向’驱动的完全不切实际的场景中。”</blockquote></p><p> Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p><p><blockquote>在哥本哈根和纽约上市的Orphazyme目前预计2021年的运营亏损为6.70-7亿克朗（107-1.12亿美元），而此前的预测为亏损100-1.5亿克朗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-18 16:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p><p><blockquote>Orphazyme股价在盘前交易中暴跌超过60%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p><p><blockquote>在美国卫生监管机构拒绝其关键候选药物后，Orphazyme周五大幅下调了财务预测。</blockquote></p><p> Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p><p><blockquote>Orphazyme表示，其申请FDA批准arimoclomol（一种治疗遗传性疾病尼曼-皮克病C型的药物）的申请尚未成功。</blockquote></p><p> As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p><p><blockquote>因此，该公司预计今年的收入将低于此前预期，运营亏损将大幅扩大，迫使该公司削减成本。</blockquote></p><p> \"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p><p><blockquote>经纪商Nordnet在给客户的一份报告中写道：“Orphazyme没有钱，也没有实质性的项目……投资者将资金投入到‘模因倾向’驱动的完全不切实际的场景中。”</blockquote></p><p> Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p><p><blockquote>在哥本哈根和纽约上市的Orphazyme目前预计2021年的运营亏损为6.70-7亿克朗（107-1.12亿美元），而此前的预测为亏损100-1.5亿克朗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664632,"gmtCreate":1624006870226,"gmtModify":1631892937482,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like n comment!","listText":"like n comment!","text":"like n comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664632","repostId":"2144005727","repostType":4,"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":129024813,"gmtCreate":1624346278732,"gmtModify":1631890740940,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129024813","repostId":"1136223229","repostType":4,"repost":{"id":"1136223229","kind":"news","pubTimestamp":1624345984,"share":"https://www.laohu8.com/m/news/1136223229?lang=zh_CN&edition=full","pubTime":"2021-06-22 15:13","market":"us","language":"en","title":"\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136223229","media":"zerohedge","summary":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same","content":"<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p><p><blockquote>持续的全球半导体短缺导致电子产品价格上涨，同时迫使供应商和材料提供商继续提高价格。在短缺的情况下，对消费电子产品的需求持续飙升。</blockquote></p><p> Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p><p><blockquote>因此，据《新华尔街日报》报道，行业官员认为价格上涨可能会继续。这种影响在消费电子产品中很容易看到。</blockquote></p><p> The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p><p><blockquote>该报告指出，像一台华硕笔记本电脑以前售价900美元，现在售价950美元。一台惠普Chromebook笔记本电脑过去售价220美元，现在价格涨到了250美元。事实上，惠普在短短一年内就将消费PC价格提高了8%，将打印机价格提高了20%以上。该公司首席执行官将价格上涨归咎于“零部件短缺”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p><p><blockquote>戴尔科技公司首席财务官Thomas Sweet最近表示：<b>“当我们考虑零部件成本上涨时，我们将酌情调整定价。”</b></blockquote></p><p> Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p><p><blockquote>伯恩斯坦分析师托尼·萨科纳吉<s>为惠普找借口</s>对价格上涨的解释是，它们反映了缺乏通常的折扣，而不是全面的价格上涨。</blockquote></p><p> Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p><p><blockquote>芯片制造商Analog Devices Inc.的首席执行官Vincent Roche评论道：“我们没有利用这个周期在定价方面做任何事情，除了为我们必须获得的额外供应支付更多费用。我们正在传递这一点。”</blockquote></p><p> Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p><p><blockquote>博通公司首席执行官Hock Tan简单地指出：“我们看到了成本通胀。”</blockquote></p><p> Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p><p><blockquote>Digi-Key Electronics今年还将半导体相关组件的价格提高了约15%。他们将此归咎于“供应紧缩的压力”。<b>该公司全球供应商管理副总裁David Stein表示，某些零部件现在的成本比以前高出40%。</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p><p><blockquote>“自去年年初以来，计算机内存的合同价格上涨了约34%。”<i>杂志</i>指出，物价上涨是“美国经济通胀更广泛上升的一部分”。</blockquote></p><p> The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p><p><blockquote>根据Supplyframe Inc.的数据，自去年年中以来，最畅销的20款微控制器的中值价格上涨了12%以上。</blockquote></p><p> Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p><p><blockquote>电子元器件行业协会首席分析师戴尔·福特总结道：<b>“原材料成本最近上涨更多，我认为人们现在说这不是暂时的情况。价格上涨将是持久的。”</b></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher<blockquote>“这不是暂时的情况”：全球芯片短缺将继续推高价格</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-06-22 15:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p><p><blockquote>持续的全球半导体短缺导致电子产品价格上涨，同时迫使供应商和材料提供商继续提高价格。在短缺的情况下，对消费电子产品的需求持续飙升。</blockquote></p><p> Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p><p><blockquote>因此，据《新华尔街日报》报道，行业官员认为价格上涨可能会继续。这种影响在消费电子产品中很容易看到。</blockquote></p><p> The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p><p><blockquote>该报告指出，像一台华硕笔记本电脑以前售价900美元，现在售价950美元。一台惠普Chromebook笔记本电脑过去售价220美元，现在价格涨到了250美元。事实上，惠普在短短一年内就将消费PC价格提高了8%，将打印机价格提高了20%以上。该公司首席执行官将价格上涨归咎于“零部件短缺”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p><p><blockquote>戴尔科技公司首席财务官Thomas Sweet最近表示：<b>“当我们考虑零部件成本上涨时，我们将酌情调整定价。”</b></blockquote></p><p> Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p><p><blockquote>伯恩斯坦分析师托尼·萨科纳吉<s>为惠普找借口</s>对价格上涨的解释是，它们反映了缺乏通常的折扣，而不是全面的价格上涨。</blockquote></p><p> Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p><p><blockquote>芯片制造商Analog Devices Inc.的首席执行官Vincent Roche评论道：“我们没有利用这个周期在定价方面做任何事情，除了为我们必须获得的额外供应支付更多费用。我们正在传递这一点。”</blockquote></p><p> Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p><p><blockquote>博通公司首席执行官Hock Tan简单地指出：“我们看到了成本通胀。”</blockquote></p><p> Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p><p><blockquote>Digi-Key Electronics今年还将半导体相关组件的价格提高了约15%。他们将此归咎于“供应紧缩的压力”。<b>该公司全球供应商管理副总裁David Stein表示，某些零部件现在的成本比以前高出40%。</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p><p><blockquote>“自去年年初以来，计算机内存的合同价格上涨了约34%。”<i>杂志</i>指出，物价上涨是“美国经济通胀更广泛上升的一部分”。</blockquote></p><p> The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p><p><blockquote>根据Supplyframe Inc.的数据，自去年年中以来，最畅销的20款微控制器的中值价格上涨了12%以上。</blockquote></p><p> Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p><p><blockquote>电子元器件行业协会首席分析师戴尔·福特总结道：<b>“原材料成本最近上涨更多，我认为人们现在说这不是暂时的情况。价格上涨将是持久的。”</b></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136223229","content_text":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.\nErgo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.\nThe report notes that items like one ASUS laptop that formerly cost $900 now costs $950. An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".\nDell Technologies Inc. Chief Financial Officer Thomas Sweet recently said: “As we think about component cost increases, we’ll adjust our pricing as appropriate.”\nBernstein analyst Toni Sacconaghimade excuses for HPexplained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.\nVincent Roche, the CEO of chip maker Analog Devices Inc., commented: “We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”\nHock Tan, CEO of Broadcom Inc., simply noted: “We see cost inflation.”\nDigi-Key Electronics has also raised prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".Certain components now cost 40% more than they used to, according to David Stein, the company’s vice president of global supplier management.\n\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the Journalnotes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".\nThe median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to Supplyframe Inc.\nDale Ford, the chief analyst at the Electronic Components Industry Association, concluded: “Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,"SPY":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154864,"gmtCreate":1624606929858,"gmtModify":1631890740830,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/122154864","repostId":"1169758731","repostType":4,"isVote":1,"tweetType":1,"viewCount":1382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285619,"gmtCreate":1624465614931,"gmtModify":1631890740868,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121285619","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027304,"gmtCreate":1624346321408,"gmtModify":1631890740897,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129027304","repostId":"2145033651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024568,"gmtCreate":1624346293054,"gmtModify":1631890740926,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129024568","repostId":"1139414035","repostType":4,"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154699,"gmtCreate":1624606940611,"gmtModify":1631890740816,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122154699","repostId":"2146027771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167303200,"gmtCreate":1624245214400,"gmtModify":1631892937410,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167303200","repostId":"2145707918","repostType":4,"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164045216,"gmtCreate":1624162915335,"gmtModify":1631892937432,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164045216","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166652695,"gmtCreate":1624007827517,"gmtModify":1631892937456,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"good!!","listText":"good!!","text":"good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166652695","repostId":"1164089282","repostType":4,"isVote":1,"tweetType":1,"viewCount":311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692253758,"gmtCreate":1641003778376,"gmtModify":1641003778376,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253758","repostId":"1114332157","repostType":4,"isVote":1,"tweetType":1,"viewCount":2153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253123,"gmtCreate":1641003752634,"gmtModify":1641003752726,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253123","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":121269818,"gmtCreate":1624465750834,"gmtModify":1631890740844,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121269818","repostId":"1127255730","repostType":4,"isVote":1,"tweetType":1,"viewCount":3106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027014,"gmtCreate":1624346306138,"gmtModify":1631890740911,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"man","listText":"man","text":"man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027014","repostId":"1161295709","repostType":4,"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167309877,"gmtCreate":1624245184099,"gmtModify":1631892937423,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167309877","repostId":"2145700634","repostType":4,"isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164042708,"gmtCreate":1624162897804,"gmtModify":1631892937445,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":":0","listText":":0","text":":0","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164042708","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664750,"gmtCreate":1624006893770,"gmtModify":1631892937476,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":":00","listText":":00","text":":00","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664750","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://www.laohu8.com/m/news/1142916683?lang=zh_CN&edition=full","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p><p><blockquote>Orphazyme股价在盘前交易中暴跌超过60%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p><p><blockquote>在美国卫生监管机构拒绝其关键候选药物后，Orphazyme周五大幅下调了财务预测。</blockquote></p><p> Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p><p><blockquote>Orphazyme表示，其申请FDA批准arimoclomol（一种治疗遗传性疾病尼曼-皮克病C型的药物）的申请尚未成功。</blockquote></p><p> As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p><p><blockquote>因此，该公司预计今年的收入将低于此前预期，运营亏损将大幅扩大，迫使该公司削减成本。</blockquote></p><p> \"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p><p><blockquote>经纪商Nordnet在给客户的一份报告中写道：“Orphazyme没有钱，也没有实质性的项目……投资者将资金投入到‘模因倾向’驱动的完全不切实际的场景中。”</blockquote></p><p> Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p><p><blockquote>在哥本哈根和纽约上市的Orphazyme目前预计2021年的运营亏损为6.70-7亿克朗（107-1.12亿美元），而此前的预测为亏损100-1.5亿克朗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading<blockquote>Orphazyme股价在盘前交易中暴跌超过60%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-18 16:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p><p><blockquote>Orphazyme股价在盘前交易中暴跌超过60%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p><p><blockquote>在美国卫生监管机构拒绝其关键候选药物后，Orphazyme周五大幅下调了财务预测。</blockquote></p><p> Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p><p><blockquote>Orphazyme表示，其申请FDA批准arimoclomol（一种治疗遗传性疾病尼曼-皮克病C型的药物）的申请尚未成功。</blockquote></p><p> As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p><p><blockquote>因此，该公司预计今年的收入将低于此前预期，运营亏损将大幅扩大，迫使该公司削减成本。</blockquote></p><p> \"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p><p><blockquote>经纪商Nordnet在给客户的一份报告中写道：“Orphazyme没有钱，也没有实质性的项目……投资者将资金投入到‘模因倾向’驱动的完全不切实际的场景中。”</blockquote></p><p> Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p><p><blockquote>在哥本哈根和纽约上市的Orphazyme目前预计2021年的运营亏损为6.70-7亿克朗（107-1.12亿美元），而此前的预测为亏损100-1.5亿克朗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285710,"gmtCreate":1624465639130,"gmtModify":1631890740866,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"Nioo","listText":"Nioo","text":"Nioo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121285710","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":2707,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664632,"gmtCreate":1624006870226,"gmtModify":1631892937482,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"like n comment!","listText":"like n comment!","text":"like n comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664632","repostId":"2144005727","repostType":4,"isVote":1,"tweetType":1,"viewCount":417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692251955,"gmtCreate":1641003795174,"gmtModify":1641003795174,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692251955","repostId":"2195448557","repostType":4,"isVote":1,"tweetType":1,"viewCount":2813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":129027708,"gmtCreate":1624346334604,"gmtModify":1631890740882,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573902637171983","idStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027708","repostId":"1186855284","repostType":4,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=zh_CN&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<p>  On a strong day for the Nasdaq, two highfliers stood out.  Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-22 14:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  On a strong day for the Nasdaq, two highfliers stood out.  Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq  was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}